Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and carboplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.

This is written in the approval document as:

Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations

Reimbursement

Incomplete Reimbursement

Pembrolizumab - ODMS; Pemetrexed, Carboplatin - N/A

Citation

Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6891/568_V5_Pembrolizumab_PEMEtrexed_CARBOplatin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-02-01	Health Service Executive	Indication approved for reimbursement.